Treatment of Lambert-Eaton myasthenic syndrome with 3,4-diaminopyridi
Not Applicable
Recruiting
- Conditions
- ambert-Eaton myasthenic syndrome
- Registration Number
- JPRN-UMIN000024055
- Lead Sponsor
- Tokushima University
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 10
Inclusion Criteria
Not provided
Exclusion Criteria
Minors, pregnant women, or patients with a past history of epilepsy
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method The compound muscle action potential(CMAP) and the degree of increase in CMAP amplitude after high frequency receptive nerve stimulation conducted 1, 2, 4 months after treatment.
- Secondary Outcome Measures
Name Time Method